The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review

被引：8

作者：

Jahangiri, Soodeh ^{[1
]}

Malek, Mojtaba ^{[2
]}

Kalra, Sanjay ^{[3
,4
]}

Khamseh, Mohammad E. ^{[1
]}

机构：

[1] Iran Univ Med Sci, Inst Endocrinol & Metab, Endocrine Res Ctr, Tehran, Iran

[2] Iran Univ Med Sci, Inst Endocrinol & Metab, Res Ctr Prevent Cardiovasc Dis, Tehran, Iran

[3] Bharti Hosp, Dept Endocrinol, Karnal, India

[4] Chandigarh Univ, Univ Ctr Res & Dev, Mohali, India

来源：

DIABETES THERAPY | 2023年 / 14卷 / 12期

关键词：

SGLT2; inhibitors; Type; 2; DM; DXA; BIA; Muscle mass; FAT-FREE MASS; WEIGHT-LOSS; GLYCEMIC CONTROL; DOUBLE-BLIND; MUSCLE MASS; DAPAGLIFLOZIN; IPRAGLIFLOZIN; CROSSOVER; INSULIN; ADULTS;

D O I：

10.1007/s13300-023-01481-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Body composition is related to cardiometabolic disorders and is a major driver of the growing incidence of type 2 diabetes mellitus (T2DM). Altered fat distribution and decreased muscle mass are related to dysglycemia and impose adverse health-related outcomes in people with T2DM. Hence, improving body composition and maintaining muscle mass is crucial in T2DM. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering medications gaining popularity because of their cardiorenal-protective effects and weight-lowering characteristics. However, reports on myopathy secondary to SGLT2 inhibitor treatment raised a safety concern. The importance of maintaining muscle mass in people with T2DM necessitates further investigation to explore the impact of novel medications on body composition. In this review, we discussed current evidence on the impact of SGLT2 inhibitors on body composition in people with T2DM.

引用

页码：2015 / 2030

页数：16

共 85 条

[1] Can anthropometric indices predict the chance of hypertension? A multicentre cross-sectional study in Iran [J].

Akbari-khezrabadi, Ali ;

Zibaeenezhad, Mohammad Javad ;

Shojaeefard, Ehsan ;

Naseri, Arzhang ;

Mousavi, Shahrokh ;

Sarejloo, Shirin ;

Karimi, Mohammadreza ;

Hosseinpour, Morteza ;

Salimi, Maryam ;

Bazrafshan, Mehdi ;

Salimi, Amirhossein ;

Parsa, Nader ;

Sayadi, Mehrab ;

Razeghian-Jahromi, Iman ;

Zibaeenejad, Fatemeh ;

Mohammadi, Seyyed Saeed ;

Drissi, Hamed Bazrafshan .

BMJ OPEN, 2022, 12 (11)

[2]

[Anonymous], 2011, Br J Diabetes Vasc Dis, DOI [10.1177/1474651411413644, DOI 10.1177/1474651411413644]

[3] Body Weight Considerations in the Management of Type 2 Diabetes [J].

Apovian, Caroline M. ;

Okemah, Jennifer ;

O'Neil, Patrick M. .

ADVANCES IN THERAPY, 2019, 36 (01) :44-58

[4] Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice [J].

Bamba, Ryo ;

Okamura, Takuro ;

Hashimoto, Yoshitaka ;

Majima, Saori ;

Senmaru, Takafumi ;

Ushigome, Emi ;

Nakanishi, Naoko ;

Asano, Mai ;

Yamazaki, Masahiro ;

Takakuwa, Hiroshi ;

Hamaguchi, Masahide ;

Fukui, Michiaki .

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2022, 13 (01) :574-588

[5] Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks [J].

Blonde, Lawrence ;

Stenlof, Kaj ;

Fung, Albert ;

Xie, John ;

Canovatchel, William ;

Meininger, Gary .

POSTGRADUATE MEDICINE, 2016, 128 (04) :371-380

[6] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].

Bolinder, J. ;

Ljunggren, O. ;

Johansson, L. ;

Wilding, J. ;

Langkilde, A. M. ;

Sjostrom, C. D. ;

Sugg, J. ;

Parikh, S. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169

[7] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

[8] Advanced body composition assessment: from body mass index to body composition profiling [J].

Borga, Magnus ;

West, Janne ;

Bell, Jimmy D. ;

Harvey, Nicholas C. ;

Romu, Thobias ;

Heymsfield, Steven B. ;

Leinhard, Olof Dahlqvist .

JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (05) :887-895

[9] Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial [J].

Brandt-Jacobsen, Niels H. ;

Jurgens, Mikkel ;

Hasbak, Philip ;

Gaede, Peter ;

Rossing, Peter ;

Rasmussen, Jon J. ;

Andersen, Camillla Fuchs ;

Forman, Julie L. ;

Faber, Jens ;

Inzucchi, Silvio E. ;

Gustafsson, Finn ;

Schou, Morten ;

Kistorp, Caroline .

DIABETES OBESITY & METABOLISM, 2023, 25 (03) :844-855

[10] Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities [J].

Brown, Emily ;

Wilding, John P. H. ;

Barber, Thomas M. ;

Alam, Uazman ;

Cuthbertson, Daniel J. .

OBESITY REVIEWS, 2019, 20 (06) :816-828

← 1 2 3 4 5 6 7 8 9 →